Clinical Trials Browser

Phase 3 × human papillomavirus vaccine, L1 type 16, 18 × Clear all

Uterine Cervical Neoplasms

NCT03728881 2025-08-03

PRIMAVERA

Phase 3 Completed

1,240 enrolled 107 charts

Gynecologic

Human Papillomavirus-Related Cervical Carcinoma

NCT00481767 2020-11-17

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

Phase 3 Completed

676 enrolled 15 charts

Infections, Papillomavirus Infections

NCT01381575 2020-06-09

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Phase 3 Completed

1,447 enrolled 26 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01627561 2020-04-10

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Phase 3 Completed

148 enrolled 28 charts

Papillomavirus Infections

NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Phase 3 Completed

152 enrolled 21 charts

Gynecologic

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

NCT00250276 2020-01-02

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

Phase 3 Completed

798 enrolled 19 charts

Papillomavirus Infections

NCT00294047 2020-01-02

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Phase 3 Completed

5,752 enrolled 42 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00423046 2020-01-02

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Phase 3 Completed

1,106 enrolled 27 charts

Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT01462357 2019-11-15

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Phase 3 Completed

1,079 enrolled 26 charts

Papillomavirus Infections

NCT01249365 2019-11-13

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Phase 3 Completed

199 enrolled 9 charts

Papillomavirus Infections

NCT01190176 2019-10-30

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Phase 3 Completed

34 enrolled 12 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01190189 2019-06-19

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Phase 3 Completed

137 enrolled 9 charts

Papillomavirus Infections

NCT00128661 2019-03-08

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Phase 3 Completed

7,466 enrolled 24 charts

GynecologicOther neoplasm

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

NCT00492544 2018-09-04

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Phase 3 Completed

100 enrolled 9 charts

Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00122681 2018-08-20

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Phase 3 Completed

18,729 enrolled 35 charts

Papillomavirus Infections

NCT00578227 2018-08-17

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

814 enrolled 28 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00344032 2018-07-20

Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women

Phase 3 Completed

354 enrolled 12 charts

Papillomavirus Infections

NCT00485732 2018-07-20

A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years

Phase 3 Completed

225 enrolled 14 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00799825 2018-07-12

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Phase 3 Completed

346 enrolled 8 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00337818 2017-05-30

Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women

Phase 3 Completed

770 enrolled 12 charts

Gynecologic

Uterine Cervical Dysplasia

NCT00811798 2016-10-20

Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.

Phase 3 Completed

92 enrolled 6 charts

Papillomavirus Infections

NCT02082639 2015-07-20

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

Phase 3 Withdrawn

Papillomavirus Infections

NCT02100618 2015-07-20

Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

Phase 3 Withdrawn

Papillomavirus Infections

NCT00316706 2012-09-18

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

Phase 3 Completed

1,245 enrolled 11 charts

Gynecologic

Uterine Cervical Dysplasia, Papillomavirus Infections

Clinical Trials

DoRIS

PRIMAVERA

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women

A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women

Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine